Literature DB >> 32678927

Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy.

Kylie M Quinn1,2, Apriliana E R Kartikasari1, Rachel E Cooke3,4, Rachel M Koldej3,4, David S Ritchie3,4, Magdalena Plebanski1.   

Abstract

Many cancers are predominantly diagnosed in older individuals and chronic inflammation has a major impact on the overall health and immune function of older cancer patients. Chronic inflammation is a feature of aging, it can accelerate disease in many cancers and it is often exacerbated during conventional treatments for cancer. This review will provide an overview of the factors that lead to increased inflammation in older individuals and/or individuals with cancer, as well as those that result from conventional treatments for cancer, using ovarian cancer (OC) and multiple myeloma (MM) as key examples. We will also consider the impact of chronic inflammation on immune function, with a particular focus on T cells as they are key targets for novel cancer immunotherapies. Overall, this review aims to highlight specific pathways for potential interventions that may be able to mitigate the impact of chronic inflammation in older cancer patients. ©2020 Society for Leukocyte Biology.

Entities:  

Keywords:  IL-1; IL-6; TNF; multiple myeloma; ovarian cancer

Mesh:

Substances:

Year:  2020        PMID: 32678927     DOI: 10.1002/JLB.5MR0520-466R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

Review 1.  Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis.

Authors:  Apriliana E R Kartikasari; Cesar S Huertas; Arnan Mitchell; Magdalena Plebanski
Journal:  Front Oncol       Date:  2021-07-07       Impact factor: 6.244

Review 2.  T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy.

Authors:  Palak H Mehta; Salvatore Fiorenza; Rachel M Koldej; Anthony Jaworowski; David S Ritchie; Kylie M Quinn
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

3.  Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.

Authors:  Chia Sharpe; Joanne E Davis; Kylie Mason; Constantine S Tam; Rachel M Koldej; David S Ritchie
Journal:  J Transl Med       Date:  2021-11-22       Impact factor: 5.531

4.  Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.

Authors:  Celia Martín-Otal; Aritz Lasarte-Cia; Diego Serrano; Noelia Casares; Enrique Conde; Flor Navarro; Inés Sánchez-Moreno; Marta Gorraiz; Patricia Sarrión; Alfonso Calvo; Carlos E De Andrea; José Echeveste; Amaia Vilas; Juan Roberto Rodriguez-Madoz; Jesús San Miguel; Felipe Prosper; Sandra Hervas-Stubbs; Juan Jose Lasarte; Teresa Lozano
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

Review 5.  The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.

Authors:  Zhigang Yi; Tao Ma; Jia Liu; Wenting Tie; Yanhong Li; Jun Bai; Lijuan Li; Liansheng Zhang
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

Review 6.  Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression.

Authors:  Momodou Cox; Apriliana E R Kartikasari; Paul R Gorry; Katie L Flanagan; Magdalena Plebanski
Journal:  Biomedicines       Date:  2021-03-30

7.  Elevated Interleukin-6 Levels in the Circulation and Peritoneal Fluid of Patients with Ovarian Cancer as a Potential Diagnostic Biomarker: A Systematic Review and Meta-Analysis.

Authors:  Hina Amer; Apriliana E R Kartikasari; Magdalena Plebanski
Journal:  J Pers Med       Date:  2021-12-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.